Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Status:
Completed
Trial end date:
2015-01-12
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of the trial is to investigate the
pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of
oral semaglutide (NNC0113-0217) in subjects with mild, moderate and severe degrees of hepatic
impairment compared to subjects with normal hepatic function.